List AF - Search Results

1

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Fenaux P, et al. Among authors: list af. J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2. J Hematol Oncol. 2017. PMID: 28651604 Free PMC article. Clinical Trial.

2

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, Hamblin T, Hellstrom-Lindberg E, List A, Mufti G, Neuwirtova R, Ohyashiki K, Oscier D, Sanz G, Sanz M, Willman C. Greenberg P, et al. J Clin Oncol. 2000 Oct 1;18(19):3447-52. doi: 10.1200/JCO.2000.18.19.3447. J Clin Oncol. 2000. PMID: 11013289 No abstract available.

3

Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P. List A, et al. Leukemia. 2003 Aug;17(8):1499-507. doi: 10.1038/sj.leu.2403021. Leukemia. 2003. PMID: 12886236 Review.

4

Efficacy of lenalidomide in myelodysplastic syndromes.

List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. List A, et al. N Engl J Med. 2005 Feb 10;352(6):549-57. doi: 10.1056/NEJMoa041668. N Engl J Med. 2005. PMID: 15703420 Free article. Clinical Trial.

5

Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?

Sekeres MA, List A. Sekeres MA, et al. Curr Hematol Rep. 2005 May;4(3):182-5. Curr Hematol Rep. 2005. PMID: 15865869 Review.

6

Alternative treatments for myelodysplastic syndromes.

Sekeres M, List A. Sekeres M, et al. Semin Hematol. 2005 Jul;42(3 Suppl 2):S32-7. doi: 10.1053/j.seminhematol.2005.05.008. Semin Hematol. 2005. PMID: 16015503 Review.

7

Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).

List AF. List AF. Semin Oncol. 2005 Aug;32(4 Suppl 5):S31-5. doi: 10.1053/j.seminoncol.2005.06.020. Semin Oncol. 2005. PMID: 16085015 Review.

8

New agents in the treatment of MDS.

List AF. List AF. Clin Adv Hematol Oncol. 2005 Nov;3(11):832-4. Clin Adv Hematol Oncol. 2005. PMID: 16491623 No abstract available.

9

Myelodysplastic syndrome.

Nakao S, Deeg HJ, Ishikawa T, Marsh J, List A, Tomonaga M. Nakao S, et al. Int J Hematol. 2005 Dec;82(5):412-6. doi: 10.1532/IJH97.05139. Int J Hematol. 2005. PMID: 16533744 Free article. No abstract available.

10

Lenalidomide: an immunomodulatory drug.

Crane E, List A. Crane E, et al. Future Oncol. 2005 Oct;1(5):575-83. doi: 10.2217/14796694.1.5.575. Future Oncol. 2005. PMID: 16556034 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page